EGI
RXDX

EAM Global Investors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

EAM Global Investors’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-22,893
Closed -$2.52M – 214
2022
Q4 		$2.52M Sell
22,893
-50,863
-69% -$3.3M 0.65% 38
2022
Q3 		$4.35M Buy
+73,756
New +$3.37M 1.16% 13
2022
Q2 		– Sell
-57,073
Closed -$2.15M – 285
2022
Q1 		$2.15M Hold
57,073
– – 0.4% 114
2021
Q4 		$2.26M Buy
+57,073
New +$1.79M 0.4% 134

Other funds holding RXDX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM Global Investors's RXDX Position: Q1 2023 in Review

EAM Global Investors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q1 2023, closing a stake of 22,893 shares — an estimated $2.52M sold.

EAM Global Investors first reported a position in RXDX in Q4 2021 and held it in 4 quarters. The position peaked at $4.35M in Q3 2022. 219 funds tracked by Wall St. Rank hold RXDX as of Q1 2023.

  • EAM Global Investors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • EAM Global Investors sold 22,893 Prometheus Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $2.52M.
  • EAM Global Investors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • EAM Global Investors's Prometheus Biosciences, Inc. Common Stock position peaked at $4.35M in Q3 2022.
  • 219 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q1 2023.

Based on EAM Global Investors's 13F filing for Q1 2023, filed 15 May 2023.